Roland Magnusson/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) posted around 5% Y/Y higher revenues to $11.5B for Q3, missing consensus estimates. The top-line was weighed
Roland Magnusson/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) posted around 5% Y/Y higher revenues to $11.5B for Q3, missing consensus estimates. The top-line was weighed